Nearly All Anesthesiologists Report Drug Shortages
Drug substitutions or changes in administration of the medications has also resulted in increased costs for patient sand the healthcare system, the ASA said. Longer operating room recovery times are another negative consequence stemming from the use of less optimal anesthesia medications, with 49% of respondents reporting that impact.
Anesthesia medications were identified as one of three categories of medications, along with oncology and anti-infective drugs, according to a U.S. Government Accountability Office report on drug shortages in December.
"Our analysis of the causes of 15 sterile injectable drug shortages (involving 5 anesthesia drugs, 5 anti-infective drugs, and 5 oncology drugs) showed that manufacturing problems were the primary cause of most shortages, and over half were exacerbated by multiple difficulties after the drug initially went into short supply," the report said.
The GAO recommended that "Congress should consider establishing a requirement for manufacturers to report to FDA any changes that could affect the supply of their drugs. In addition, FDA should enhance its ability to respond to drug shortages, for example, by developing an information system to manage data about shortages. HHS outlined actions it plans to take that are consistent with GAO’s recommendations."
Cheryl Clark is senior quality editor and California correspondent for HealthLeaders Media. She is a member of the Association of Health Care Journalists.
- Primary Care Docs Average More Hospital Revenue Than Specialists
- How Chargemaster Data May Affect Hospital Revenue
- $6.4B Henry Ford, Beaumont Merger Failed on Cultural Hurdles
- House Lawmakers Grill CMS Over Health Exchange Navigators
- Fortunately, Angelina Jolie Isn't On Medicare
- ED Physicians Key to Half of Hospital Admissions
- Insurer's App Aims to Lower Healthcare Costs, Securely
- 69% of Employers Plan to Offer Healthcare Coverage After 2014
- Don't Let Nurses Sink Your Bottom Line
- Q&A: Catholic Health Initiatives' New Senior VP for Capital Finance

Comments are moderated. Please be patient.